These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19322212)

  • 1. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
    Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
    Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omacetaxine as an anticancer therapeutic: what is old is new again.
    Wetzler M; Segal D
    Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.
    Okabe S; Tauchi T; Tanaka Y; Katagiri S; Kitahara T; Ohyashiki K
    Blood; 2013 Oct; 122(17):3086-8. PubMed ID: 24159169
    [No Abstract]   [Full Text] [Related]  

  • 6. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
    Quintás-Cardama A; Cortes J
    IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
    Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
    Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omacetaxine mepesuccinate for the treatment of leukemia.
    Kim TD; Frick M; le Coutre P
    Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.
    Mahadeo KM; Cole PD
    Blood; 2010 May; 115(18):3852. PubMed ID: 20448119
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
    Chen Y; Peng C; Sullivan C; Li D; Li S
    Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
    Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
    Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
    Nicolini FE; Chomel JC; Roy L; Legros L; Chabane K; Ducastelle S; Nicolas-Virelizier E; Michallet M; Tigaud I; Magaud JP; Turhan A; Guilhot F; Hayette S
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):394-9. PubMed ID: 21030353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
    Chung C
    Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omacetaxine mepesuccinate in chronic myeloid leukemia.
    Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
    Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Narayanan V; Gutman JA; Pollyea DA; Jimeno A
    Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
    Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
    Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
    Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
    Wang Q; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.